Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide / bortezomib / dexamethasone and in lenalidomide maintenance treatment
- Conditions
- ewly diagnosed symptomatic multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2017-004768-37-DE
- Lead Sponsor
- Ruprecht-Karls-University Heidelberg, Medical Faculity, represented by University Hospital Heidelberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 662
- Confirmed diagnosis of untreated multiple myeloma requiring systemic therapy (diagnostic criteria (IMWG updated criteria (2014)). For some patients systemic therapy may be required though these diagnostic criteria are not fulfilled. In this case the GMMG study office has to be consulted prior to inclusion.
- Patient is eligible for high dose therapy and autologous stem cell transplantation.
- Measurable disease, defined as any quantifiable monoclonal protein value, defined by at least one of the following three measurements:
• Serum M-protein = 10g/l (for IgA = 5g/l)
• Urine light-chain (M-protein) of = 200 mg/24 hours
• Serum FLC assay: involved FLC level = 10 mg/dl and abnormal sFLC ratio
- Age 18 - 70 years inclusive
- WHO performance status 0-2
- Negative pregnancy test at inclusion (women of childbearing potential)
- For all men and women of childbearing potential: patients must be willing and capable to use adequate contraception during the complete therapy. Patients must agree on the requirements regarding the lenalidomide pregnancy prevention programme
- All patients must:
• agree to abstain from donating blood while taking lenalidomide and for 28 days following discontinuation of lenalidomide therapy
• agree not to share study drug lenalidomide with another person and to return all unused study drug to the investigator or pharmacist
- Ability of patient to understand character and individual consequences of the clinical trial
- Provide written informed consent (must be available before enrolment in the trial)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 530
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 132
- Patient has known hypersensitivity (or contraindication) to dexamethasone, sucrose histidine (as base and hydrochloride salt), boron, mannitol, and polysorbate 80 or any of the components of study therapy that are not amenable to premedication with steroids or H2 blockers that would prohibit further treatment with these agents.
- Systemic AL amyloidosis (except for AL amyloidosis of the skin or the bone marrow)
- Plasma cell leukemia
- Previous chemotherapy or radiotherapy during the past 5 years except local radiotherapy in case of local myeloma Progression or benign diseases, such as non-malignant thyroid diseases. (Note: patients may have received a cumulative dose of up to 160 mg of dexamethasone or equivalent as emergency therapy.) Previous therapy due to smouldering myeloma may be acceptable. In this case the GMMG study office has to be consulted prior to inclusion.
- Severe cardiac dysfunction (NYHA classification III-IV)
- Significant hepatic dysfunction (ASAT and/or ALAT = 3 times normal level and/or serum bilirubin = 1.5 times normal level if not due to hereditary abnormalities as Gilbert’s disease), unless related to myeloma.
- Patients with active or history of hepatitis B or C (Prior hepatitis B may be acceptable if an adequate prophylaxis is being implemented during the course of the study.)
- HIV positivity
- Patients with active, uncontrolled infections
- Patients with severe renal insufficiency (Creatinine Clearance < 30ml/min)
- Patients with peripheral neuropathy or neuropathic pain, CTC grade 2 or higher (as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0)
- Patients with a history of active malignancy during the past 5 years with the exception of the following malignancies after curative therapy: basal cell carcinoma of the skin, squamous cell skin carcinoma, stage 0 cervical carcinoma or any in situ malignancy (A history of an early stage malignancy during the past 5 years may be acceptable. In this case the GMMG study office has to be consulted prior to study inclusion.)
- Patients with acute diffuse infiltrative pulmonary and/or pericardial disease
- Autoimmune hemolytic anemia with positive Coombs test or immune thrombocytopenia
- Platelet count < 75 x 10^9/l (Platelet transfusions are not permitted to improve platelet count prior to study inclusion.)
- Haemoglobin = 8.0 g/dl, unless related to myeloma
- Absolute neutrophil count (ANC) < 1.0 x 10^9/l (the use of colony stimulating factors within 14 days before the test is not allowed)
- Corrected serum calcium > 14 mg/dl (> 3.5 mmol/l)
- Unable or unwilling to undergo thromboprophylaxis
- Pregnancy and lactation
- Participation in other clinical trials. This does not include long-term follow-up periods without active drug treatment of previous studies during the last 6 months.
- Prisoners or subjects who are legally institutionalized, or those unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
No patients will be allowed to enrol in this trial more than once.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method